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Epidemiology
 
Type 2 diabetes mellitus (DM), formerly known as
non-insulin-dependent diabetes mellitus (NIDDM),
accounts for 75–90% of cases of diabetes, de-
pending upon ethnic background. The prevalence
of type 2 DM in Western countries has tradition-
ally been estimated at between two and six per-
cent, of which half the patients are diagnosed and
a similar number unrecognized. However, this fig-
ure is now known to be much higher in older peo-
ple and non-whites. Over the age of 65 years, 10–
20 percent of individuals are likely to be affected.
In the nonwhite populations living in a western
culture (e.g., Asians in the UK, Pacific Islanders,
Pima Indians), between 10 and 40 percent of total
adult populations have type 2 DM (see Table 1)
[1]. It is estimated that the number of patients
worldwide with type 2 DM will rise from 157 mil-
lion in the year 2000–215 million by 2010 [2].
The regions with the greatest potential increase
are Asia and Africa where diabetes could become
two to three times more common than it is today.
It is estimated that Asia will have 61% of this
worldwide projected increased number of people
with type 2 DM by the year 2010. It is felt that life-
style changes, with diets high in saturated fat and
decreased physical activity, together with increased
longevity, are the main factors in this explosion of
type 2 DM. The problem may be aggravated by
intrauterine malnutrition [3]. More detailed analy-
sis of these global estimates of diabetes as we enter
the new millennium has recently been undertaken,
reviewing the problem in different continents [4].
Type 2 DM has previously been erroneously re-
ferred to as mild diabetes because it is often as-
ymptomatic in terms of the classical symptoms of
diabetes such as thirst and polyuria. However, it
should be recognized as a silent killing disease
where cardiovascular disease (CVD) is the princi-
pal cause of death for about 70 percent of type 2
DM patients [5]. Accelerating atherosclerosis may
be present for many years before the onset of clin-
ical diabetes. The life expectancy of a type 2 DM
patient is reduced by between 30 and 40 percent
for those in the age range of 40–70 years, a loss of
eight to 10 years of life [6].
 
Characteristic Features of Type 2 Diabetes
 
The principal underlying defects in type 2 DM are
a reduced sensitivity to the action of insulin (called
insulin resistance) combined with an impaired abil-
 
ity of the 
 

 
-cells of the pancreas to secrete suffi-
cient insulin to overcome this resistance. Patients
can have predominant beta-cell dysfunction, espe-
cially if not overweight, or predominant insulin
resistance, especially if they are obese (which is
usually the case). A late-onset type 1 DM is also
recognized in patients over 65 years of age with
predominantly 
 

 
-cell dysfunction and presenting
with a clinical picture of type 2 DM. This has been
classified as late-onset autoimmune diabetes of
adults (LADA) and identified by the presence of
circulating antibodies to glutamic acid decarboxy-
lase (GAD).
Type 2 DM begins insidiously and progresses
slowly over many years. Initially, there may be
few symptoms and after years of unrecognized dis-
ease patients may present with complications of
diabetes at diagnosis (see below). The characteris-
tic features of type 2 DM are summarized in Ta-
ble 2. Genetic factors appear to play a role with
regard to both the insulin resistance and impaired
pancreatic 
 

 
-cell function. However, it is well rec-
ognized that environmental factors also play a ma-
jor role in the development of type 2 DM, and as
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mentioned above, these are principally high calo-
rie intake and limited physical activity so that obe-
sity is present in 70% of type 2 DM patients. In-
deed, it is now recognized that type 2 DM is not a
distinct clinical entity but rather a complex of risk
factors for CVD. Type 2 DM is now better de-
scribed as an insulin resistance syndrome or a met-
abolic syndrome, originally described by Reaven
in 1988 as Syndrome X [7]. The syndrome de-
scribes the clustering together of certain cardio-
vascular risk factors associated with insulin resis-
tance, the principal ones being obesity, glucose
intolerance, hypertension and an abnormal lipid
profile of high triglyceride levels with decreased
HDL-cholesterol.
 
Clinical Presentation of Type 2 Diabetes
 
Type 2 DM may present to the clinician in one of
4 ways:
• Classical symptoms;
• Incidental diagnosis;
• Complications of diabetes mellitus;
• Hyperosmolar nonketotic coma.
 
Classical Symptoms
 
Symptoms of type 2 DM that may be seen at diagno-
sis are thirst, polyuria, fatigue and malaise, infections
(especially genital candidiasis), and blurred vision.
These symptoms, seen usually in older individuals,
are not usually as severe in nature or as sudden in
onset as those seen in younger type 1 (or insulin-
dependent) DM, where there is a different aetiology
causing the diabetes, namely an immune-mediated
destruction of the pancreatic 
 

 
-cells.
 
Incidental Diagnosis
 
Type 2 DM may be an incidental finding. Oppor-
tunistic urine and blood testing for glucose is often
done in older individuals at the time of intercur-
rent illness, either at the primary or secondary
care level, or as part of an annual health check. In
population surveys, up to 50% of type 2 DM pa-
tients are relatively asymptomatic at diagnosis.
 
Complications of Diabetes
 
It is important to recognise that all diabetic pa-
tients are at risk of complications and type 2 DM
may present with complications. Most of the mor-
bidity and mortality associated with type 2 DM is
attributable to the chronic complications of diabe-
tes (Table 3). Diabetic complications have two
major subdivisions:
1. Microvascular complications, which are spe-
cific to diabetes mellitus and do not occur in
nondiabetic subjects. They are sometimes re-
ferred to as specific complications of diabetes.
The principal sites that are damaged are the eye
(retinopathy), the kidney (nephropathy) and
the nervous system (neuropathy) and the clini-
cal consequences can be blindness, renal failure
and foot problems with risk of amputation.
2. Macrovascular complications which are not
unique to diabetes but occur much more com-
monly in diabetic subjects. They are often termed
nonspecific complications. The main large vessels
that are involved are those supplying the heart,
the brain and the legs (see Table 3). Thus, mac-
rovascular disease gives rise to heart attack,
stroke and gangrene.
 
Hyperosmolar Nonketotic Coma (HONK)
 
HONK is a form of diabetic coma seen in older
type 2 DM patients. It is often seen at diagnosis in
previously undiagnosed subjects. HONK is often
associated with the introduction of thiazide or ste-
roid therapy or seen after a major vascular event
 
Table 1
 
Effects of race and age on prevalence of diabetes 
mellitus in Western cultures*
 
Age
20–44 years 45–74 years
Non-Hispanic White 1.6% 12.0%
Black 3.3% 19.3%
Mexican Americans 3.8% 23.9%
Pima Indians 40% 65%
South-Asian Indians 16–20%
 
*Data adapted from Harris M (ed.) Diabetes in America, 2
 
nd
 
 edition. New
York: US Department of Health and Human Services, 1995.
 
Table 2
 
Characteristic features of type 2 DM
 

 
Onset usually occurs in patients 
 

 
30 years of age
 

 
Onset is often insidious
 

 
Positive family history in 30% of cases
 

 
Almost 100% concordance in identical twins
 

 
No association with HLA; no islet cell antibodies (as in type 1 DM)
 

 
Symptoms controlled by diet and/or oral hypoglycemic drugs; 
insulin treatment may be required later in the disease
 
Table 3
 
Chronic complications of type 2 DM
 
Microvascular disorders
 
➢
 
Retinopathy
 
➢
 
Nephropathy
 
➢
 
Neuropathy
 
➢
 
Foot problems
Macrovascular disorders ➢ Cardiovascular disease
➢ Cerebrovascular disease
➢ Peripheral vascular disease
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such as myocardial infarction or stroke. The pa-
tient presenting with HONK is usually drowsy or
unconscious and severely dehydrated. Hospital
treatment is urgent to give the subject intravenous
fluids and insulin therapy, although after recov-
ery, about 50% of patients will have satisfactory
glucose control without insulin, by means of diet
and oral hypoglycemic drugs.
 
Microvascular Disease and Type 2 DM
 
Diabetic Retinopathy
 
In Western countries diabetes mellitus is the most
common cause of blindness in people between the
ages of 20 and 60 years. About five to 10 percent
of type 2 DM patients may have retinopathy at the
time of diagnosis because of the insidious onset of
the disease. This figure will rise to 30% at 10
years after diagnosis. In type 2 DM patients the
threat to vision is from diabetic maculopathy
which affects central vision. Laser photocoagula-
tion therapy is successful in prevention of blind-
ness in about 60–70% of patients treated pro-
vided the retinopathy is detected early. Therefore,
regular screening for retinopathy at annual inter-
vals is essential.
 
Diabetic Nephropathy
 
Diabetic renal disease affects 15–20% of type 2
DM subjects, in 50% of whom it will progress to
renal failure. The incidence and prevalence are
two to three times greater in those of Asian ethnic-
ity. Diabetic nephropathy is now becoming the
single most common cause of end stage renal fail-
ure. In Europe, over 10% of patients requiring di-
alysis or transplantation have diabetes mellitus
and this figure is twice as high in the USA.
 
Diabetic Neuropathy
 
The commonest form of nerve damage is that of
chronic peripheral neuropathy where appreciation
of touch and pain are lost, followed by loss of
proprioception in the lower limbs. The feet are
numb, easily damaged by heat or minor trauma
and ulceration can occur. Diabetic peripheral neu-
ropathy is difficult to treat and the most impor-
tant aspect of management is patient education in
the basic principles of good foot care.
 
Diabetic Foot Problems
 
Foot problems are a major cause of morbidity in
type 2 DM and one of the most common reasons
for hospital admissions in diabetes mellitus. The
diabetic foot represents a spectrum of disorders
ranging from vascular insufficiency, neuropathy
and infection, to gangrene. Chronic sensory neur-
opathy (numb feet) is a major factor in 70–80% of
diabetic foot ulcers and is usually a permanent
feature. Preventive foot care is therefore essential
in type 2 DM patients. The education of the pa-
tient in the basic principles of good foot care is es-
sential and all patients must be seen regularly by a
podiatrist.
 
Macrovascular Disease and Type 2 DM
 
Cardiovascular Disease
 
This is the major cause of death and hospitaliza-
tion in type 2 DM subjects. Acute myocardial inf-
arction (heart attack) is about two to four times
more common in type 2 DM patients than in the
general population and mortality from cardiac
failure and heart attacks is also higher. A recent
study from Finland showed that a diagnosis of
type 2 DM, without a previous heart attack, carried
a similar risk as that in the nondiabetic subject
who had sustained a previous myocardial infarction,
clearly illustrating type 2 DM as a potent cardiovas-
cular risk factor [8]. The United Kingdom Prospec-
tive Diabetes Study (UKPDS) identified increasing
age, blood glucose control, increased systolic blood
pressure, raised LDL-cholesterol levels with reduced
HDL-cholesterol levels and smoking as significant
risk factors for CAD in type 2 DM patients [9].
 
Cerebrovascular Disease
 
Acute ischemic stroke and transient cerebral is-
chemic attacks are three to four times more common
in type 2 DM.
 
Peripheral Vascular Disease
 
The incidence of peripheral vascular disease is in-
creased by up to six-fold in type 2 DM. It may
present as intermittent claudication, ulceration or
gangrene. Lower limb amputation is up to 20
times more common in type 2 DM subjects.
In clinical practice, intervention techniques for
diabetic macrovascular disease are often disappoint-
ing because of the severity and widespread nature of
the atherosclerotic vascular disease. Most patients
with type 2 DM die prematurely of macrovascular
disease. Macrovascular mortality is 50% after 10
years of overt type 2 DM. Prevention is felt to be the
best method of approaching the problem, but in
type 2 DM especially, the disease may be diagnosed
late after years of occult glucose intolerance in mid-
dle-aged individuals who already have extensive
macrovascular disease at diagnosis. The early diag-
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nosis of type 2 DM is important. Recent guidelines
have stressed the importance of strict glucose, blood
pressure and lipid control in type 2 diabetic subjects
[10–12]. This morbidity and premature mortality is
putting increased pressure on health care resources
[13]. The UK Prospective Diabetes Study (UKPDS)
has shown that in type 2 DM subjects good blood
glucose control [14] and tight blood pressure con-
trol [15] can prevent complications or delay their
progression. The early detection of retinopathy,
nephropathy and neuropathy can lead to a reduc-
tion in the incidence of blindness, kidney failure and
amputation due to diabetes.
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